Hikma Pharmaceuticals (LON:HIK) Stock Price Passes Above 200-Day Moving Average – What’s Next?

Hikma Pharmaceuticals PLC (LON:HIK) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,450.19 and traded as high as GBX 1,496. Hikma Pharmaceuticals shares last traded at GBX 1,475.83, with a volume of 658,113 shares.

Wall Street Analyst Weigh In

HIK has been the topic of several recent research reports. Jefferies Financial Group upped their price objective on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,800 price objective on shares of Hikma Pharmaceuticals in a report on Tuesday, April 28th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of GBX 2,128.

Hikma Pharmaceuticals Stock Down 0.3%

The company has a fifty day moving average of GBX 1,409.13 and a two-hundred day moving average of GBX 1,450.19. The company has a market cap of £3.14 billion, a PE ratio of 8.15, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65. The company has a debt-to-equity ratio of 63.59, a quick ratio of 1.27 and a current ratio of 1.82.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.